RNS Number : 3894L
ValiRx PLC
29 April 2020

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Statement re social media reports

London, UK., *29 April 2020*: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, notes the recent movement in the Company's share price and speculative comments posted on social media in respect of a potential Joint Venture in relation to the Company's non-core intellectual property - GeneICE, TRAC and BioFit.

The Company confirms that it is in talks with a third-party in relation to a Joint Venture. However, there is no certainty the talks will conclude in a successful manner, nor that in the event that the Joint Venture is agreed, that the terms will be favourable to the Company.

-ENDS-

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:

ValiRx plc **Tel: +44 (0)207 0732628**
www.valirx.com
Kevin Alexander - Non-executive Director

Cairn Financial Advisers LLP (Nominated Adviser) **Tel: +44 (0) 20 7213 0880**
Liam Murray / Jo Turner / Ludovico Lazzaretti

Peterhouse Capital Limited (Sole Broker) **Tel: +44 (0) 20 7469 0930**
Duncan Vasey / Lucy Williams / Eran Zucker

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCSEUFMUESSEDL